BC Innovations | May 23, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Animal models A Drosophila larval movement-based model could be used to screen therapies for fragile X syndrome. The model involves generating Drosophila larvae at the third instar stage of development that harbor one of...
BC Innovations | Jul 31, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain LIM domain kinase 1 (LIMK1); LIMK2 Rat studies suggest inhibiting LIM domain kinases could help treat inflammation- and heat-induced pain. Rats subjected to both...
BC Week In Review | Aug 27, 2012
Clinical News

LX7101: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 63 patients with glaucoma showed that 0.125% and 0.25% doses of LX7101 for 2 weeks were well tolerated with no serious adverse events or withdrawals due to...
BC Innovations | Oct 7, 2010
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer LIM domain kinase 1 (LIMK1); LIMK2 Studies in cell culture suggest that inhibiting LIMK1 and LIMK2 could help treat...
BC Innovations | Oct 29, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Ophthalmic disease Glaucoma; ocular hypertension LIM domain kinase 2 (LIMK2) In vitro and mouse studies identified inhibitors of LIMK2 that could help treat ocular hypertension....
Items per page:
1 - 5 of 5